Navigation Links
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
Date:5/11/2011

PARSIPPANY, N.J., May 11, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL™, and reiterated 2011 financial guidance.

"During the first quarter we have continued to work closely with hospitals and physicians to evaluate the clinical and favorable economic impact EXPAREL may offer patients and the healthcare system," said David Stack, president and chief executive officer of Pacira Pharmaceuticals, Inc. "Our retrospective health economics research studies are well underway and are successfully demonstrating that the postsurgical use of opioid analgesia often leads to increased, and often avoidable, resource utilization. At the same time, we are pushing forward with a number of targeted prospective clinical studies to examine the impact of utilizing EXPAREL instead of morphine administered in a PCA (patient controlled analgesia) setting. We believe that these programs, combined with our robust pipeline of awareness and educational activities, will position EXPAREL for rapid adoption among key opinion leaders should it receive approval from the U.S. Food and Drug Administration (FDA) later this year."

Financial Highlights

  • Net loss for the quarter ended March 31, 2011 was $9.8 million, or $0.98 per share, compared with $5.4 million, or $9.39 per share, for the quarter ended March 31, 2010.
  • Total revenues for the quarter ended March 31, 2011 were $3.9 million compared with $4.8 million for the first quarter of 2010. The $0.9 million decrease was primarily attributable to $1.2 million decline in supply revenue, from $2.9 million in the first quarter of 2010 to $1.7 million in the first quarter of 2011 and reflect
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
    2. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
    3. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    4. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    5. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    6. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    10. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    11. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)... , October 1, 2014 ... Next Generation Sequencing (NGS) data analysis, today launches a ... cystic fibrosis analysis in a single NGS experiment. The ... all types of variants in a single NGS experiment ... it has not been possible to simultaneously analyse all ...
    (Date:9/30/2014)... MARIETTA, Ga. , Sept. 30, 2014 ... leading regenerative medicine company utilizing human amniotic tissue and ... therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports ... Dr. Tom Koob , Ph.D., Chief Scientific Officer, ... Mesa. Dr. Koob will present on Tuesday, October 7, ...
    (Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
    Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2MiMedx to Present at the Stem Cell Meeting on the Mesa 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
    ... At the 10th Asian Forum on Corporate Responsibility ... and its philanthropic foundation the Abbott Fund were honored ... advancing science education in the region.  Abbott Science Education ... innovative events designed to spark an interest in life-long ...
    ... Mass. and TORONTO, Oct. 24, 2011 Generex Biotechnology ... the Company is planning an investor update conference call ... to provide investors with an update on (i) the ... previously announced spinout of its wholly-owned immunotherapeutics subsidiary, Antigen ...
    Cached Medicine Technology:Abbott Honored With Asian CSR Award for Leadership in Science Education 2Abbott Honored With Asian CSR Award for Leadership in Science Education 3Generex Announces Investor Update Conference Call Planned for Late November 2Generex Announces Investor Update Conference Call Planned for Late November 3
    (Date:10/2/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... major highway may raise your risk for high blood pressure, ... women, those who lived within 109 yards of a busy ... blood pressure than women living at least half a mile ... highlight the importance of our physical environment on our health ...
    (Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, ... the stops to rescue surgical patients in crisis are ... such heroism is questionable, a new study suggests. ... saving elderly patients with life-threatening complications after major surgery, ... senior author Dr. Amir Ghaferi. He is assistant professor ...
    (Date:10/1/2014)... Adelaide have developed a model that could help to ... treatment - from their very first psychotic episode. , ... including clinical symptoms, cognitive abilities, MRI scans of the ... Speaking in the lead up to World Mental Health ... , Professor Bernhard Baune , says the model ...
    (Date:10/1/2014)... study published today in the Journal of the ... than 50 years with moderate or severe chronic knee ... from the University of Melbourne randomly assigned 282 patients ... no acupuncture or sham or pretend laser treatment. ... and acupuncturists blinded to laser and sham (inactive) laser ...
    (Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
    Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Predicting the future course of psychotic illness 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
    ... but critics want agency to act, not wait years ... ads on television should include a toll-free phone number ... U.S. health experts suggested Friday. , The experts serve ... Drug Administration. Such phone numbers are already mandated by ...
    ... Workers, WASHINGTON, May 16 More than ... Portland, Oregon and,Vancouver, Washington area have ratified their ... that these workers are now covered by a,strong ... secure retirement,future," said Teamsters General President Jim Hoffa., ...
    ... benefit from calcitriol, an oral form , , FRIDAY, May 16 ... risk of death for people with moderate to severe chronic ... , During a two-year study of more than 1,400 ... activated vitamin D, had their overall risk of death lowered ...
    ... what did you,say?" is a phrase being used more ... Americans, that is 1 in 9 individuals, have,significant hearing ... rate.,Thirteen out of every 100 school age children have ... attention to this social and economic problem,is what led ...
    ... for May 19 at 10:15 a.m. Eastern Time, ... (TSX: RBM, OTCBB: RPBIF) today announced that S. ... at the Rodman & Renshaw,5th Annual Global Healthcare ... A live web cast of the presentation ...
    ... needs is more unemployed politicians - and economists, ... health care at the top of their "most-important issues" ... health care plans,advanced by any of the current presidential ... U.S. Senate Majority Leader Bill Frist., Jousting with ...
    Cached Medicine News:Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3
    Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
    Bard® Channel Drain...
    ... Used for stone manipulation ... duct. The nitinol memory wire ... its shape following extreme torsion. ... the likelihood of mucosal damage ...
    Used for serial post-operative cholangiography and the placement of a wire guide to facilitate post-operative E.R.C.P. Supplied sterile in peel-open packages. Intended for one-time use....
    Medicine Products: